Effect of Inhaled Coricosteroids on Serum TNF-α HDAC2 and PTX3 Levels in Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
LIU Ting, LI Yang, SHI Zhihong, et al
The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Xi'an 710061, China
Abstract：Objective: To observe the effects of inhaled coricosteroids on the levels of serum tumor necrosis factor-α (TNF-α), histone deacetylase 2 (HDAC2) and pentraxin 3 (PTX3) in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: One hundred and thirty patients with AECOPD admitted to our hospital from January 2020 to December 2021 were selected and divided into two groups using the coin toss grouping method. Both groups were given conventional symptomatic treatment, the control group was additionally given terbutaline nebulizer inhalation treatment, and the observation group was treated with combined inhaled corticosteroids on the basis of the control group. The differences of symptom and sign scores, pulmonary function, blood routine, TNF-α, HDAC2 and PTX3 were compared between the two groups, and the adverse effects were counted in both groups. Results: Before treatment, there was no statistically significant difference between the two groups in terms of symptom and sign scores and pulmonary function (P>0.05). Compared with before treatment, the scores of cough, sputum, shortness of breath, and lung auscultation decreased after treatment in both groups, and the decrease values were greater in the observation group before and after treatment than in the control group (P<0.05). The first second force expiratory volume (FEV1) and FEV1/forced vital capacity (FVC) increased after treatment in both groups, and the increased values were greater in the observation group before and after treatment than in the control group (P<0.05).Before treatment, there were no statistically significant differences in TNF-α, HDAC2, PTX3, and routine blood indices between the two groups (P>0.05). Compared with before treatment, neutrophil percentage (NE%), TNF-α, neutrophil-to-lymphocyte ratio (NLR), HDAC2, white blood cell count (WBC), and PTX3 decreased after treatment in both groups, and the decrease value was greater in the observation group before and after treatment than in the control group (P<0.05). Lymphocyte percentage (LY%) increased in both groups after treatment, and the increase was greater in the observation group before and after treatment than in the control group (P<0.05). Two cases of hoarseness and one case of hoarseness occurred in the control group and the observation group, respectively, and no adverse reactions such as pharyngeal discomfort and blood glucose elevation occurred.Conclusion: Inhaled coricosteroids for AECOPD can reduce symptoms such as cough and sputum and improve lung function, which may be related to reducing the expression of TNF-α, HDAC2 and PTX3.
刘婷, 李洋, 石志红, 杨岚. 雾化吸入性糖皮质激素对慢性阻塞性肺疾病急性加重住院患者血清TNF-α HDAC2及PTX3水平的影响[J]. 河北医学, 2023, 29(5): 814-819.
LIU Ting, LI Yang, SHI Zhihong, et al. Effect of Inhaled Coricosteroids on Serum TNF-α HDAC2 and PTX3 Levels in Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. HeBei Med, 2023, 29(5): 814-819.
[1] Gershon A S,Chung H,Porter J,et al.Influenza vaccine effectiveness in preventing hospitalizations in older patients with chronic obstructive pulmonary disease[J].The Journal of Infectious Diseases,2020,221(1):42-52. [2] 陈碧,刘文静,张毛为,等.含糖皮质激素吸入制剂在支气管哮喘和慢性阻塞性肺疾病中的合理应用[J].中华结核和呼吸杂志,2021,44(8):765-768. [3] 吴美景,梁梅兰,吴玉丹,等.肝素结合蛋白与正五聚蛋白3联合检测对慢性阻塞性肺疾病急性加重期患者细菌感染的预测价值[J].中国感染与化疗杂志,2020,20(6):652-658. [4] Yu S,Zhang J,Fang Q,et al.Blood eosinophil levels and prognosis of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease[J].The American Journal of the Medical Sciences,2021,362(1): 56-62. [5] 唐晓霞,翁军,韩静.特布他林联合多索茶碱对慢性阻塞性肺疾病患者的疗效及患者呼吸动力学的影响[J].中国医院药学杂志,2020,40(15):1659-1662. [6] 陈伟光,温剑锋.AECOPD患者呼吸道病毒感染的病原菌及炎症因子检测结果分析[J].海南医学,2021,32(12):1530-1533. [7] 王蕾,邱宇,王娟,等.无创高频振荡通气在中-重度慢性阻塞性肺疾病急性加重期伴呼吸衰竭患者中的应用[J].成都医学院学报,2022,17(1):16-20.
2023, Vol. 29 
冀公网安备13080202000677号